Quarter Business Highlights

Principal Financial Data

Fiscal year
(millions of yen)
ending March 2022/Q1 (JGAAP) ending March 2022/Q1~2 (JGAAP) ending March 2022/Q1~3 (JGAAP) ending March 2022/Q1~4 (JGAAP) ending March 2023/Q1 (IFRS) ending March 2023/Year Ended (forecast) (IFRS)
Net sales 41,157 71,568 106,218 137,547 35,619 134,000
 Pharmaceuticals 37,050 63,430 93,625 120,650 30,407 115,000
 Functional food 4,106 8,138 12,593 16,897 5,211 19,000
Operating income 16,448 21,504 29,321 28,299 10,276 27,000
Ordinary income 16,598 22,250 30,563 29,773 - -
Net income attributable to owners of the parent 12,341 16,561 22,606 23,044 8,249 21,500
Depreciation and amortization 1,453 2,933 5,200
Capital investment 1,102 4,264 8,500
R&D expenses 3,699 10,005 15,706 26,386 4,738 24,400
Total assets 200,114 204,052 204,795 210,052 219,684
Net assets / Total equity 170,465 174,890 177,240 176,767 185,227

Net Sales

Operating income
 

Net income attributable to owners of the parent

R&D expenses

Cash Flows

Fiscal year
(millions of yen)
ending March 2022/Q1 (JGAAP) ending March 2022/Q1~2 (JGAAP) ending March 2022/Q1~3 (JGAAP) ending March 2022/Q1~4 (JGAAP) ending March 2023/Q1 (IFRS)
Cash flow from operating activities 13,333 16,018 3,872
Cash flow from investing activities -1,954 △6,359 △1,566
Cash flow from financing activities -3,365 △6,801 △4,289

Long-term Chronological Data

View long-term chronological data from here.